Cover Image
市場調查報告書

注意力不足過動症(簡稱過動症)(ADHD):全球臨床實驗趨勢

Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2017

出版商 GlobalData 商品編碼 172336
出版日期 內容資訊 英文 519 Pages
訂單完成後即時交付
價格
Back to Top
注意力不足過動症(簡稱過動症)(ADHD):全球臨床實驗趨勢 Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2017
出版日期: 2017年04月30日 內容資訊: 英文 519 Pages
簡介

本報告提供注意力不足過動症(ADHD)相關之臨床研究最新趨勢分析,提供疾病·治療方法概要,及G7、E7各國的臨床實驗狀況,各地區、各階段的進行狀況,並彙整有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 前五名國家的臨床實驗數量; 亞太地區
    • 前五名國家的臨床實驗數量; 歐洲
    • 主要國家的臨床實驗數量; 北美
    • 主要國家的臨床實驗數量; 中東/非洲地區
    • 主要國家的臨床實驗數量; 中南美

G7各國的臨床實驗數量:注意力不足過動症(ADHD) 臨床實驗數量佔中樞神經系統臨床實驗數量比率

各期臨床實驗數量:G7各國

G7各國的臨床實驗數量:各進展狀況

E7各國的臨床實驗數量:注意力不足過動症(ADHD) 臨床實驗數量佔中樞神經系統臨床實驗數量比率

各期臨床實驗數量:E7各國

E7各國的臨床實驗數量:各進展狀況

各期臨床實驗數量

  • 各期的進展中臨床實驗數量

各進展狀況臨床實驗數量

各評估項目臨床實驗數量

一定期間所採用的受驗人數

贊助商類別的臨床實驗數量

有潛力的贊助商

臨床實驗主要參加企業 - 注意力不足過動症(ADHD) 治療藥

有潛力的藥劑

最新臨床實驗新聞:注意力不足過動症(ADHD)

臨床實驗簡介的基本資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

GlobalData's clinical trial report, "Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2017" provides an overview of Attention Deficit Hyperactivity Disorder (ADHD) clinical trials scenario. This report provides top line data relating to the clinical trials on Attention Deficit Hyperactivity Disorder (ADHD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials 28
  • Prominent Drugs 29
  • Latest Clinical Trials News on Attention Deficit Hyperactivity Disorder (ADHD) 30
  • Apr 21, 2017: Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Children with ADHD 30
  • Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD 30
  • Apr 18, 2017: NLS Pharma Announces Completion of Phase 2 Study for NLS-1, Its Lead ADHD Compound; New Investors, New Patents 31
  • Apr 12, 2017: Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Study of Novel Drug Candidate Dasotraline Being Evaluated in the Treatment of Children with Attention Deficit Hyperactivity Disorder 32
  • Apr 12, 2017: Ironshore Pharmaceuticals Announces Positive HLD100 Results from Open-Label Tolerability Study in Pediatric ADHD Patients 32
  • Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD 33
  • Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001 33
  • Feb 09, 2017: Tris Pharma's Results from a Laboratory Classroom Study of DYANAVEL XR in Children with ADHD Featured at APSARD 34
  • Clinical Trial Profile Snapshots 35

Appendix 516

  • Abbreviations 516
  • Definitions 516
  • Research Methodology 517
  • Secondary Research 517
  • About GlobalData 518
  • Contact Us 518
  • Source 519

List of Tables

List of Tables

  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 14
  • Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 15
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 18
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Phase, 2017* 21
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29

List of Figures

List of Figures

  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 10
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 13
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 14
  • Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 15
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Attention Deficit Hyperactivity Disorder (ADHD) to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 18
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 21
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 22
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 26
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
  • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29
  • GlobalData Methodology 517
Back to Top